Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Drugs. 2023 Sep;83(13):1239-1244. doi: 10.1007/s40265-023-01922-4.
Sovateltide (Tycamzzi™), a highly selective endothelin-B receptor agonist and synthetic analog of endothelin-1, is being developed by Pharmazz, Inc. as a neural progenitor cell therapeutic agent for the treatment of acute cerebral ischemic stroke (ACIS), hypoxic-ischemic encephalopathy (HIE), spinal cord injuries and Alzheimer's disease. In May 2023, sovateltide was approved in India for the treatment of cerebral ischemic stroke within 24 h of stroke onset. This article summarizes the milestones in the development of sovateltide leading to this first approval for use in patients with ACIS.
索瓦托替肽（TycamzziTM）是一种高度选择性的内皮素-B 受体激动剂和内皮素-1 的合成类似物，由 Pharmazz, Inc. 开发，作为一种神经祖细胞治疗剂，用于治疗急性脑缺血性中风（ACIS）、缺氧缺血性脑病（HIE）、脊髓损伤和阿尔茨海默病。2023 年 5 月，索瓦托替肽在印度获得批准，用于治疗中风发作后 24 小时内的脑缺血性中风。本文总结了索瓦托替肽开发过程中的重要里程碑，最终使其首次获准用于 ACIS 患者的治疗。
